ResearcherHirosaki UniversityActive in the last 2 years
Hiroshi Kijima
Matched on ORCID iD 0000-0002-2366-9896; OpenAlex author ID A5102917355. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 14
2011: 1 paper · 2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 7
- Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2026.106238↗
- Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemothera… Last author DOI 10.3892/or.2023.8498↗
- Eukaryotic initiation factor 2 signaling behind neural invasion linked with lymphatic and vascular invasion in pancreatic cancer. Co-author DOI 10.1038/s41598-021-00727-3↗
- Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pancreatic cancer. Last author DOI 10.3892/ol.2021.12537↗
- The basic helix-loop-helix transcription factor DEC2 inhibits TGF-β-induced tumor progression in human pancreatic cancer BxPC-3 cells. Last author DOI 10.3892/ijmm.2012.1037↗
- The BHLH transcription factor DEC1 plays an important role in the epithelial-mesenchymal transition of pancreatic cancer. Last author DOI 10.3892/ijo.2012.1559↗
- L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.21880↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kenichi Hakamada · 6 shared papers, 2011–2026 · strength 0.75
- Paper Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic… DOI 10.1016/j.humpath.2026.106238↗
- Paper Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological thera… DOI 10.3892/or.2023.8498↗
- Paper Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pan… DOI 10.3892/ol.2021.12537↗
- Keinosuke Ishido · 5 shared papers, 2011–2026 · strength 0.72
- Paper Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic… DOI 10.1016/j.humpath.2026.106238↗
- Paper Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological thera… DOI 10.3892/or.2023.8498↗
- Paper Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pan… DOI 10.3892/ol.2021.12537↗
- Tadashi Yoshizawa · 4 shared papers, 2021–2026 · strength 0.70
- Paper Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic… DOI 10.1016/j.humpath.2026.106238↗
- Paper Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological thera… DOI 10.3892/or.2023.8498↗
- Paper Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pan… DOI 10.3892/ol.2021.12537↗
- Shintaro Goto · 3 shared papers, 2021–2026 · strength 0.58
- Paper Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic… DOI 10.1016/j.humpath.2026.106238↗
- Paper Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological thera… DOI 10.3892/or.2023.8498↗
- Paper Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pan… DOI 10.3892/ol.2021.12537↗
- Kenta Ogasawara · 2 shared papers, 2023–2026 · strength 0.43
- Paper Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic… DOI 10.1016/j.humpath.2026.106238↗
- Paper Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological thera… DOI 10.3892/or.2023.8498↗
- Hayato Nagase · 2 shared papers, 2021–2026 · strength 0.38
- Paper Neoadjuvant chemotherapy remodels the three-dimensional vascular architecture and immune microenvironment in pancreatic… DOI 10.1016/j.humpath.2026.106238↗
- Paper Eukaryotic initiation factor 2 signaling behind neural invasion linked with lymphatic and vascular invasion in pancreat… DOI 10.1038/s41598-021-00727-3↗
- Yusuke Wakasa · 1 shared paper, 2026 · strength 0.26
- Satoru Tsuruta · 1 shared paper, 2026 · strength 0.26
- Yoshiki Nishiyama · 1 shared paper, 2026 · strength 0.26
- Taishu Kanda · 1 shared paper, 2021 · strength 0.12
- Taiichi Wakiya · 1 shared paper, 2021 · strength 0.12
- Fuyuki Sato · 2 shared papers, 2012 · strength 0.05
- Paper The basic helix-loop-helix transcription factor DEC2 inhibits TGF-β-induced tumor progression in human pancreatic cance… DOI 10.3892/ijmm.2012.1037↗
- Paper The BHLH transcription factor DEC1 plays an important role in the epithelial-mesenchymal transition of pancreatic cance… DOI 10.3892/ijo.2012.1559↗
- Yunyan Wu · 2 shared papers, 2012 · strength 0.05
- Paper The basic helix-loop-helix transcription factor DEC2 inhibits TGF-β-induced tumor progression in human pancreatic cance… DOI 10.3892/ijmm.2012.1037↗
- Paper The BHLH transcription factor DEC1 plays an important role in the epithelial-mesenchymal transition of pancreatic cance… DOI 10.3892/ijo.2012.1559↗
- Shinji Tsutsumi · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.